NRASQ61R/K/L mutations, present in approximately half of patients with advanced BRAFV600 wild-type melanoma, are mutually exclusive with BRAFV600 mutations and activate the mitogen-activated protein kinase pathway (MAPK- or RAS-RAF-MEK-ERK-pathway) through canonical activation of RAF, MEK and ERK [1,2,3]. Here, MAP2K7 is linked to melanoma.